The 28-day , all-cause mortality rate was 33.1 % ( 116/350 ) in the rhIL-1ra treatment group , while the mortality rate in the placebo group was 36.4 % ( 126/346 ) , yielding a 9 % reduction in mortality rate ( p = .36 ) .
